Ones To Watch News
Refine Search
Biotechnology
Epitopea, a UK and Canada-based cancer immunotherapeutics company, has partnered with nucleic acid delivery specialist Genevant Sciences to develop new RNA-based therapies targeting proprietary tumor antigens. 20 December 2024
Pharmaceutical
US biotech Assembly Biosciences has announced an equity investment of $20.1 million by Gilead Sciences to purchase additional common stock in the company and an amendment to their collaboration to advance the research and development of novel antiviral therapies with $10 million in accelerated funding. 20 December 2024
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Generics
Indian generics major Zydus Lifesciences has received tentative approval from the US Food and Drug Administration (FDA) to market canagliflozin tablets, 100mg and 300mg. 15 February 2023
Biotechnology
Canadian precision meds company Fusion Pharmaceuticals has announced the acquisition from Texas, USA-based RadioMedix, of the investigational new drug application (IND) for an ongoing Phase II clinical trial. 15 February 2023
Biotechnology
Shares of US biotech Gritstone bio were up 2.23% t $2.67 pre-marker as the company, announced that it has entered into a clinical trial agreement with the National Cancer Institute (NCI), an institute of the USA’s National Institutes of Health. 15 February 2023
Biotechnology
China and USA-based Harbour BioMed saw its shares rise more than 7% to HK$3.17, after it announced an exclusive license agreement with US firm Cullinan Oncology for the development and commercial rights on HBM7008 (CLN-418) in the USA. 14 February 2023
Pharmaceutical
Shares of US ophthalmic drug developer Ocuphire Pharma were lifted 7.6% to $3.53 this morning, as the company updated on the development of its lead product candidate. 13 February 2023
Biotechnology
G1 Therapeutics’ shares fell 51.8% to $3.43 pre-market today, as the US oncology drug developer said it would terminate a study of its lead drug, trilaciclib, as it was unlikely to be effective in extending survival in patients with a type of colorectal cancer. 13 February 2023
Biotechnology
Positive Phase III data for Bristol Myers-Squibb’s Abecma (idecabtagene vicleucel) underscore the potential of the firm’s CAR-T cell therapy in multiple myeloma. 13 February 2023
Pharmaceutical
Mineralys Therapeutics, a previously private company in the portfolio of HBM Healthcare Investments, successfully completed its IPO last Friday. 13 February 2023
Biotechnology
Swedish immuno-oncology company Alligator Bioscience today announces the promotion of Laura von Schantz to the post of chief technology officer (CTO), and her joining the executive management team. 13 February 2023
Biotechnology
The US Food and Drug Administration (FDA) has verbally informed US biotech Blueprint Medicines that it has placed a partial clinical hold on the Phase I/II VELA trial of BLU-222 due to visual adverse events (AEs) observed in a limited number of patients, the company announced on Friday, with the news pushing the firm’s shares down 7.9% to $40.80 pre-market. 11 February 2023
Biotechnology
US biotech Magenta Therapeutics has announced the outcome of a review of its business, including the status of its programs, resources, and capabilities. 10 February 2023
Biosimilars
Icelandic firm Alvotech and marketing partner German drugmaker STADA Arzneimittel today announced that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT04, Alvotech’s proposed biosimilar to Stelara (ustekinumab). 9 February 2023
Biotechnology
US neurological diseases specialist Ovid Therapeutics is expanding its medical and development team with the respective appointments of industry veterans, Dr Manoj Malhotra as its chief medical officer (CMO) and Dr Toshiya Nishi as its head of epilepsy research. 8 February 2023
Biotechnology
The European Commission (EC) marketing authorization (MA) that was granted in December to US biotech Atara Biotherapies for Ebvallo (tabelecleucel) has been transferred to privately French drugmaker Pierre Fabre. 8 February 2023
Pharmaceutical
Relief Therapeutics has decided to voluntarily withdraw its planned initial public offering (IPO), the Swiss biopharma company announced today, when its shares dipped 1%. 8 February 2023
Biotechnology
Boston, USA-based Garuda Therapeutics, a company creating off-the-shelf, durable blood stem cell-based cellular therapies, is $62 million richer. 7 February 2023
Biosimilars
Privately-held Advanz Pharma has announced that it has entered into an exclusive agreement with Alvotech, an Icelandic biosimilars company, for the exclusive license and supply rights for a proposed copy of Xolair (omalizumab). 6 February 2023
Pharmaceutical
Shares of US drug developer Context Therapeutics were up more than 7% at $0.97 pre-market, after it announced that two patients enrolled in the Phase II OATH trial of ONA-XR plus anastrozole in advanced endometrial cancer) have achieved partial response (tumor shrinkage) to the treatment. 6 February 2023
Pharmaceutical
Swiss pharma company Idorsia was trading 10% lower at lunchtime on Monday. 6 February 2023
Biotechnology
Israel-based clinical-stage company Purple Biotech saw its shares gains 9.5% to 61.00 shekels today, as announced that it has entered into an agreement to acquire Netherlands-headquartered, venture capital backed Immunorizon. 2 February 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze